Literature DB >> 23619990

Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas.

Kiyoshi Asada1, Naoko Watanabe, Yohko Nakamura, Miki Ohira, Frank Westermann, Manfred Schwab, Akira Nakagawara, Toshikazu Ushijima.   

Abstract

OBJECTIVE: The CpG island methylator phenotype is strongly associated with poor survival in neuroblastomas. Neuroblastomas with the CpG island methylator phenotype include almost all neuroblastomas with MYCN amplification, and, even among neuroblastomas without MYCN amplification, have worse prognosis. At the same time, methylation of individual tumor-suppressor genes is also reported to be associated with poor survival. The purpose of this study was to compare the prognostic power of the CpG island methylator phenotype with that of methylation of individual genes.
METHODS: Methylation-specific polymerase chain reaction was performed for five individual genes (CASP8, EMP3, HOXA9, NR1I2 and CD44) in 140 Japanese and 152 German neuroblastomas. Kaplan-Meier analysis and log-rank tests were conducted to compare the survival between groups defined by methylation status.
RESULTS: Among the five individual genes, only CASP8 methylation had a significant association with poor overall survival both in Japanese (hazard ratio = 3.1; 95% confidence interval = 1.5-6.4; P = 0.002) and German (hazard ratio = 4.8; 95% confidence interval = 2.1-11; P = 0.0002) neuroblastomas. HOXA9 and NR1I2 methylation were associated with poor survival only in German neuroblastomas. On the other hand, the CpG island methylator phenotype had a strong and consistent association in Japanese (hazard ratio = 22; 95% confidence interval = 5.3-93; P = 1.5 × 10(-5)) and German (hazard ratio = 9.5; 95% confidence interval = 3.2-28; P = 4.7 × 10(-5)) neuroblastomas.
CONCLUSION: The CpG island methylator phenotype is likely to have stronger prognostic power than methylation of individual genes in neuroblastomas.

Entities:  

Keywords:  CIMP; methylation; neuroblastoma; poor survival

Mesh:

Substances:

Year:  2013        PMID: 23619990     DOI: 10.1093/jjco/hyt058

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

Review 1.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

2.  Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells.

Authors:  S M Rafiqul Islam; Yusuke Suenaga; Atsushi Takatori; Yasuji Ueda; Yoshiki Kaneko; Hidetada Kawana; Makiko Itami; Miki Ohira; Sana Yokoi; Akira Nakagawara
Journal:  Cancer Sci       Date:  2015-08-18       Impact factor: 6.716

3.  Association of RASSF1A, DCR2, and CASP8 Methylation with Survival in Neuroblastoma: A Pooled Analysis Using Reconstructed Individual Patient Data.

Authors:  Waleed M Hassan; Mohamed S Bakry; Timo Siepmann; Ben Illigens
Journal:  Biomed Res Int       Date:  2020-12-15       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.